Prognostic Value of Biomarkers in Polyneuropathy.
Launched by RIGSHOSPITALET, DENMARK · Sep 13, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how certain biological markers—called biomarkers—can help predict the outcomes for patients with polyneuropathy, a condition that affects the nerves and can cause weakness or numbness. The researchers want to understand if these biomarkers can provide important information about a patient’s prognosis, or how their condition might progress over time.
To participate in the trial, you need to be at least 18 years old and have a confirmed diagnosis of polyneuropathy, which means a healthcare provider has done a nerve test to check your nerve function. You should also be able to read and understand Danish. Participants will undergo some physical tests and assessments related to their condition. The trial is currently looking for volunteers, and everyone is welcome to apply, regardless of gender. If you or someone you know is interested in participating, it could help advance our understanding of polyneuropathy and improve care for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Minimum 18 years old.
- • Diagnosed with polyneuropathy, confirmed by nerve conduction study.
- • Can read and understand Danish.
- Exclusion Criteria:
- • Inability to perform physical tests due to comorbidity not associated to the patient's polyneuropathy.
About Rigshospitalet, Denmark
Rigshospitalet, located in Copenhagen, Denmark, is one of the leading hospitals in Scandinavia and a prominent center for clinical research and innovation. As a key academic institution affiliated with the University of Copenhagen, Rigshospitalet is dedicated to advancing healthcare through rigorous clinical trials and groundbreaking research across various medical disciplines. The hospital’s commitment to excellence is reflected in its multidisciplinary approach, collaboration with international research networks, and focus on improving patient outcomes through evidence-based practices. With state-of-the-art facilities and a team of highly qualified professionals, Rigshospitalet plays a crucial role in translating scientific discoveries into effective treatments and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Copenhagen, , Denmark
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported